| Accession |
PRJCA012556 |
| Title |
CIBI308A201 |
| Relevance |
Medical |
| Data types |
Biomarker data
|
| Organisms |
Homo sapiens
|
| Description |
the study is a randomized, open-label, multicenter, phase 2 study to evaluate efficacy and safety of IBI308 Versus Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment. The primary endpoints are Overall Survival. |
| Sample scope |
Multiisolate |
| Release date |
2023-01-20 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Innovent
|
|
NA
|
Efficacy and safety evaluation of IBI308 versus paclitaxel/irinotecan in patients with advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment: a randomized, open-label, multicenter, phase 2 study
|
|
|
| External link |
|
| Submitter |
Jianming
Xu (jianmingxu2014@163.com)
|
| Organization |
Chinese PLA General Hospital (CPLAGH) |
| Submission date |
2022-10-17 |
